About Associate Professor Aaron Schindeler

A/Prof Aaron Schindeler has spent the last 15 years dedicated to improving the health and wellbeing of children with bone and musculoskeletal genetic conditions and injuries. He works in collaboration with a multidisciplinary team of clinicians, scientists, and biomedical engineers.

A/Prof Schindeler is currently pursuing a number of research directions for which post-graduate opportunities are available.

• Antimicrobial agents for orthopaedics: cationic steroid antibiotics are an emerging class of antimicrobial drugs. These agents are able to suppress infection by multi-drug resistant bacterial strains and are highly effective in an orthopaedic setting. We are now working to improve their delivery and co-deliver them with orthopaedic implants.
• Musculoskeletal manifestations of NF1: neurofibromatosis type 1 (NF1) is a common genetic condition that can affect a range of physiological systems. Our research focuses on ameliorating the devastating focal bone defects, as well as developing new metabolic therapies for muscle weakness.
• Brittle Bone Disease: bone fragility disorders can crippling for children and currently these genetic conditions have no cure. Our research in this space has a number of active projects. First, we are working in collaboration with clinicians to discover new disease causing genes and functionally test them using CRISPR gene editing. Second, we are working in collaboration with researchers at the Centenary Institute to model brittle bone disease in patient iPS stem cells. Thirdly, we are working with researchers at the Children's Medical Research Institute to elucidate new ways to deliver gene therapy and CRISPR constructs to bone cells using adeno associated viruses (AAVs).

In addition to these major project, A/Prof is involved with a number of other collaborative projects including the testing of biomaterials for bone tissue engineering (Chemical Engineering, University of Sydney), the pharmacological delivery of bisphosphonates for cancer indications (Garvan Institute), and the design of new orthopaedic implants (EPIC lab, The Children's Hospital at Westmead).

A/Prof Schindeler is a mid-career researcher who completed his PhD in 2003. From 2004, he started a new research team examining genetic diseases affecting bone at The Children's Hospital at Westmead. Over his career he has published 69 peer-review publications, 38 since 2012 (5-year track record). Of his ~1800 citations, approximately 75% are from publications in the last 5 years. His papers have been published in top quartile of journals in the Orthopaedics, Genetics & Heredity, Biochemistry & Molecular Biology, Cell & Tissue Engineering/Materials Science, and Endocrinology & Metabolism categories. He has also authored 2 book chapters.

A/Prof Schindeler has attracted a career total of $5M in competitive funding for his group, including being a CI on 7 successful NHMRC Project Grants and 19 other competitive grants. This includes grants from the Australian Orthopaedic Research Foundation, the Neurofibromatosis Association of Australia, and the Children's Tumor Foundation. He has held a prestigious CTF Fellowship based on his strong track record of achievement in NF1 research (2009-2011). In 2013 he successfully received US Department of Defence funding as a Program Director (PD) for an NF1 muscle research grant.

A/Prof Schindeler has supervised to completion 13 Honours graduates and 6 PhD graduates. He currently supervises 6 current PhD students and 6 Honours students.

Selected publications

For a comprehensive list of Dr Schindeler's publicatons, please visit his Sydney Medical School profile page.